Micromet, Inc (f/k/a MITI)

[goingforittoday]

https://finance.yahoo.com/news/biotech-stock-review-mitesco-launch-120010528.html

Offering info:
https://finance.yahoo.com/news/mitesco-inc-announces-15-million-120010742.html

[blindjohn]

Nice tele-health news today , lets see

[fink]

I haven’t been in this in over 8 years

What’s the new story?
Ya got any share structure #s MITI was bought out, so I’d assume this shell was left for dead debt free too.

I’ve been killing it in here.
Reloaded and adding when and where I can.

It’s the real deal story too.

[ThoroughBread]

Bids keep getting hit, although there was a 1 day recovery, low .022s whackage continuously

[Penny Roger$]

~ Monday! $MITI ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $MITI ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=MITI&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=MITI&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=MITI
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=MITI#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=MITI+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=MITI
Finviz: http://finviz.com/quote.ashx?t=MITI
~ BusyStock: http://busystock.com/i.php?s=MITI&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=MITI >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[fink]

Look a few of my feloow MITIers are a bit pissed too. I was almost shocked at the buy out price.

Securities lawyers at Goldfarb
LLP are investigating whether certain officers and directors of Micromet, Inc.
(NASDAQ: MITI) violated shareholder protection laws by agreeing to a tender
offer for $11.00 per share to Amgen. Concerned Micromet investors are encouraged
to contact securities class action attorney Hamilton Lindley at 877-583-2855 or
[e-mail] about their rights and remedies for this potentially
low buyout.

[fink]

Maybe if another bidder comes in.

[fink]

Nope, It won't. This is it. and it won't go much lower either so its like money under your pillow.

I'd put it into something else that has more upward potential Like ARIA or the Father of this sector DNDN..

I'm rolling all into MWWC

[fink]

I'm too very disapointed. I was looking at MITI as the next generation to put the 7 most widley used cancer drugs to rest. I was seriously looking at $120 -$140 a share

But thats about all she can muster in the buy out. I'm selling out 100% and see yall on the next one.

Kudos for Micromet. Thats comfirmation we as a human race will kick the shit out of cancer in my life time.

[DocLee]

Is $11 Reasonable? Not to Me It Isn't!

I'm into Micromet long term since I firmly believe that just one of its products, Blinatumomab, is going to be a blockbuster and that its BiTE technology can be developed big-time. On that basis $11 is chickenfeed.

Unfortunately, Micromet's board is endorsing the bid as stated in Section C of the Recitals in the "Agreement and Plan of Merger", downloadable here:-
Merger Document

With the marked reversal of the long slow downward drift in the SP until just a few weeks ago, it is clear that someone knew that an agreed bid was being put together and decided to capitalise on it. Insider shenanigans, anybody?

[bradfrogger]

I wonder if the share price will go much beyond the $11/share?

[north40000]

MITI buy-out by AMGN for $11/share? Will this be final offer?

[fink]

Man I really hate looking at the daily ticks in here, but she is definitly looking like it wants to stay above the $8.50 line.

[fink]

Yeulp! $8.50 is all she is good for. How many times has MITI bounced off $8.50?

She just can't seem to break that ceiling. FDA approval will. DNDN has great news a few weeks ago of over all uyse, so the sector is being used. Thats a great thing. DNDN makes revenue, paves the way for MITI when Blit is approved.

[fink]

Yeah since I have $25K wrapped up in INTC and was just looking to roll that into Apple. $420 a shares would wipe me out. I know they have China and then the World to conqure, but MITI has true potentiual in my opinion. Plus my Wife's Father could use this today. The battle hes had the past 3 years is reeally wearing the old guy down. I just wonder what this would do for him If I could get my hands on it. No one wants a false hope, but dern hes disentegrating every year. One day!

[DocLee]

Gives you a warm feeling, doesn't it!!!

[fink]

Its a $120- $140 stock with FDA approval.

This is nice. I need this. Especialy at the beginning of the year.

$8.50 beast my short term expectations. And just think, I was aboit to reload in American Airlines for the 8th time.

MITI is my most favorite LT play. I should really have this in my 401K

[DocLee]

$8.4 today and going up like a rocket!

If logic has anything to do with it, blinatumomab's commercial potential has been recognised and that means it looks like it's going to be a BLOCKBUSTER.

If logic has nothing to do with it then we can expect to see the price fall due to short-termists prematurely cashing in their shares and so missing out on the huge upside.

[fink]

Still looking to break above $8 on no news. With this news I may just hold. Nice find Doc!

[DocLee]

The National Cancer Institute Shows Confidence in Blinatumomab.

The NCI has signed a Co-operative Research & Development Agreement (CRADA) with Micromet to progress blinatumomab's development against B-Cell-derived haematologic malignancies (lymphoblastic leukaemia and various lymphomas). Initially this will be in trials using blinatumomab as first-line therapy in newly diagnosed patients.

This is one more (large) piece of evidence that blinatumomab is being recognised as a significant new treatment in haematologic malignancies.

It is becoming increasingly clear that BiTE antibody therapy has a bright future ahead and this can only be good for Micromet.

Press Release

[fink]

DNDN up 50% this morning. That spells good news for us and the rest of this class of drug makers. DNDN is the first and when they hit a snag so does the sector. The last big dip was on their news that they fudged the use of their drug, This AM we get more news of expanded Pancrease use. Maybe it will stick this time.

Still looking to break above $8 on no news

[fink]

Always a good day for the first day of the year. The past month has been wash sells and now we get the buyers back.

Now what to do? Maybe we hit $8 on this trend?

[DocLee]

Impressive Trial Results for Blinatumomab at ASH 2011

Blinatumomab was once again the winner of many plaudits at the American Society of Hematology, its high efficacy being noted once more. Good commentary on Ohad Hammer's blog.

5 Winners of ASH 2011

The omens are good (touch wood!!) for a successful (and remunerative) product when all the regulatory hurdles have been jumped. Even before that the SP should sky-rocket.

[DocLee]

Clinical Trials Provide Further Evidence for Blinatumomab's Efficacy.

Clinical trial results were presented at the latest Annual Meeting of the American Society of Hematology and confirm that blinatumomab induces durable responses in patients who have relapsed on other forms of treatment. Additionally, the treatment is nowhere near as toxic as current forms of treatment.
Blinatumomab Efficacy - further evidence from Clinical Trials
The drug is proving itself and this can only be good for the SP.

[fink]

Over the past year, Micromet has traded in a range of $4.13 to $8.63 and is now
at $5.66, 37% above that low. In the last five trading sessions, the 50-day
moving average (MA) has climbed 2.4% while the 200-day MA has slid 0.2%.

So what do you make of this. From my Scottrade alert today.

[DocLee]

American Society of Hematology - December Meeting

Micromet will be presenting the updated results of their on-going studies at next month's meeting of ASH. 3 papers are particularly interesting and show that things are heading in the right direction with new avenues of treatment opening up.

All very encouraging.

Abstracts of the presentations can be downloaded from here (search on blinatumomab).

[mlkrborn]

MITI $6.31 Micromet beats by $0.06, misses on revs (MITI) 6.31 : Reports Q3 (Sep) loss of $0.17 per share, $0.06 better than the Capital IQ Consensus Estimate of ($0.23); revenues fell 32.8% year/year to $4.5 mln vs the $7.56 mln consensus. Co's cash, cash equivalents and investments were $183.1 mln as of September 30, 2011.

[fink]

MITI just wants to go Green

[fink]

It tried to punch through that .45 line today.

4 times and what a close? Thats strong looking accumulation.

Conferance on financial situation. Debt free and have enough cash to float the burn rate till 2013, so not sure whats the scope.
I'm thinking MITI just scored another marketing partner with yet another infusion of cash. JMHO

[fink]

I know, even for the established Pharmas out there. They don't know where to sell their products in a free market. The expense to bring something to market and then the hopes they must jump through.
The wife is a Medicaid contracts Manager and sales for the entire Nation for a start up here in Birmingham. Ya want to tlak about risk? Its like each state has its own little way to screw these guys and the population they are supposed to care for. Its crazy the stuff I get to see on my end.
Its almost like they wish the entire industry would just go away.
They want to give it away first to buy votes then destroy it buy pilling on the regs and restrictions. Not to mention the chargebacks and discounts they demand just to be on their lists.

I guess you never want to be a political football. The airlines where back with Carter and look what happened to that. Its the grey hound bus service now. And I mean Service!

May God Bless the Micromets of the World.

[MinnieM]

They are all risky these days...

[MinnieM]

Filings: Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001131907&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

[MinnieM]

News: http://ih.advfn.com/p.php?pid=news&symbol=MITI

[MinnieM]

MITI chart:

[fink]

Nice volume at the open today.
Pivital day for this bottom bounce. Looking to hit the ASK with some risky powder myself.

I pray it will continue to build due to this main thought as MITI goes forward.


Data from this trial, if positive, are intended to support full approval of blinatumomab

The entire FDA process in nuts. People are dying out there. My Wife's Dad is one of these victims of the FDA precess. Nuts. I keep telling her to get him to go beg MITI to be a guienne pig. What does he have to lose? Death for the next 15-20 more years?
The FDA wants to make all drugs fail safe. 100% safe. Thats not ever gonna happen. Its a counter productive view. They call it a 'Practice' for a reason. It will never be 100%.

We look forward to initiating later this quarter the first of two planned clinical trials collectively intended to support a biologics license application for full approval."

[DocLee]

Now, this is what I call an uplifting commentary!

"Fast Route to Market"

[surf1944]

7:34AM Micromet obtains FDA feedback on registration strategy for Blinatumomab in relapsed/refractory acute lymphoblastic leukemia (MITI) 5.69 : The plan incorporates advice received from the FDA within the context of a Type C meeting. "Recent feedback received from the FDA provides a roadmap to blinatumomab registration in a patient population with limited therapeutic options... We look forward to initiating later this quarter the first of two planned clinical trials collectively intended to support a biologics license application for full approval." Later this quarter, the Company plans to initiate a single-arm Phase 2 clinical study that will enroll approximately 65 adult patients with B-precursor r/r ALL. Co also reviewed with the FDA the preliminary design of a planned randomized, controlled, Phase 3 clinical study intended to evaluate the efficacy and safety of blinatumomab in comparison to chemotherapy in adult patients with r/r B-precursor ALL. Data from this trial, if positive, are intended to support full approval of blinatumomab in this patient population.

[fink]

Morning after the company update! Looking good so far.
Someone scoresd some cheapies at the open. Ya just gained a dime so far 15 min, LOL.
I do pray we break out of the $4 dollar today.
Debt free, $1BB cash infusion from Amgen. 80%+ positive results from Europe patents.
Why the FDA and the US has become such a shitty place to do buisness is beyond me. Its comming!

[fink]

http://cc.talkpoint.com/ubsx001/091911a_im/?entity=31_PX0BDX0

$1BB from Amgen, no debt and awsome response in their patients.

Definitly the pharma stock to be flipping the snot out of for free shares. I can't help but love this company.

[fink]

Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Amgen, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Nycomed and Sanofi.

[fink]

And if ya bought the Dip, you'd be up a quarter this AM!

Micromet's President and Chief Executive Officer will present a 30 minute corporate overview on September 20th at 4:30 PM ET.

The presentation will be webcast live and may be accessed by visiting the Micromet website at www.micromet.com. A replay of the webcast will also be available on the Company's website.

I do hope this is what it will take to get us kissing $6+ again.

[buffalo2222]

Awesome. Ha Ha. Laughed my butt off.

[fink]

Look at Tex taking a look in!

My gut? With FDSA approval this will be a $120- $140 stock. Thats all. Till then it will fluctuate between the low $4 to $8.

Buy the dip! LOL Look at ARIA too. Performs a bit better, but in the same class. MITI has this speaking thing comming up spelling out the work that has been done and where they are heading. They have enough cash to keep the burn rate well funded into 2013 and the last funding for shares was 6+mos ago for $10MM forgot the number of shares?10mm
This will be one of those out of the blue stocks. It will wear ya done watching every day so just flip for free shares and ride into the FDA announcements risk free.
I'm looking for $6.50 this go around.

I hope you were looking at that Chineese Tractor company I was telling you about. Up 15% today. Another that will bounce around for some killer flip for free shares.

[texkengold]

$300K whats your gut feeling now kind sir?
bro.ken
jmho

[fink]

Don't worry Buffalo. Its cool


This is the advise I always like to give. And this is the best time to give it. Well, a week ago was best! LOL

I pray Fri sell off EOD was just a typical daytrader move.
Hit a quick micro dip and it back up above $4.80 and climbing. I want to see %6.50

[buffalo2222]

Watch this Youtube video. Funny
and vulgar, but true of 99% of
pinky stocks, especially MITI

[fink]

Yea thats always funny what they put out. Set your sights low so when it really gets back up above $6.50 they look like some real stock pickers.
My dog saw MITI as a buy a few days ago. Geeze.

[DocLee]

Encouraging - BUT with a sting in its tail!

Seeking Alpha

Now, does that make me happy or sad?

[n4807g]

Goldman Sachs Starts Micromet (MITI) at Neutral

Goldman Sachs initiates coverage on Micromet (NASDAQ: MITI) with a Neutral ratign and $5 price ...
http://www.streetinsider.com/New+Coverage/Goldman+Sachs+Starts+Micromet+%28MITI%29+at+Neutral/6724357.html

An interesting development

[FreeNorth]

Nice article. Thanks Yahoo, but could ya name a few names next time. Sounds like us.

Not MITI's antibody method but directly modifying the T-cells themselves. From the article

In this issue of the Journal, Porter and colleagues5 describe a heavily pretreated patient with chronic lymphocytic leukemia (CLL) who had a complete remission associated with the tumor lysis syndrome after adoptive immunotherapy with second-generation anti-CD19 chimeric antigen receptor–modified T cells. Four days after receiving chemotherapy with pentostatin and cyclophosphamide for depletion of lymphocytes, the patient received 1.42×107 transduced T cells over 3 days with no additional cytokines. Unselected peripheral-blood T cells were infected with a self-inactivating lentiviral vector carrying genes for the chimeric antigen receptor. These genes included the single-chain Fv from the hypervariable region of a human CD19-specific murine antibody, a hinge region, and human 4-1BB and CD3-zeta signaling domains.

CD19 is the target of MT103